And in order to improve the response rate and reduce drug-related adverse reactions, patients with bladder cancer often receive PD-L1/PD1 inhibitors therapy depending on their PD-L1 status [29], which indicates the PD-L1 expression level is still one of the main factors that determine the efficacy of PD1/PD-L1 inhibitors. This evidence concerns the gene CD274 and urinary bladder carcinoma.